Adult Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
The study will last approximately 47 weeks and may include about 15 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participant must have type 2 diabetes
-Participant must be naïve to diabetes injectable therapies and have not used any oral antihyperglycemic medications (OAM) during the 2 months preceding screening
-Participant must have hemoglobin A1c ≥7.0% and ≤9.5%
-Participant must be of stable weight
-Participant must have a BMI ≥23 kilograms per meter squared (kg/m2)
-Participant must not have type 1 diabetes
-Participant must not have pancreatitis
-Participant must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
-Participant must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
-Participant must not have been taking weight loss drugs, including over-the-counter medications during the last 3 months